Prevention of Venous Thromboembolism Disease in Emergency Departments (PREVENU)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The appropriate use of thromboprophylaxis in medical patients admitted to hospital can substantially reduce the overall burden of disease due to venous thromboembolism. However, the use of thromboprophylaxis in medical setting appears to be generally poor leaving at-risk patients unprotected.
We aim to analyse the incidence of symptomatic thromboembolic disease following hospitalisation in medical setting and the efficacy of a multicomponent prevention approach in emergency department including systematic evaluation of thrombosis risk factors and remembers of thrombophylaxis indications and modalities for acutely ill medical patients.
Design: cluster randomized interventional study - Observational study at patient level
Setting: 30 French emergency departments
Patients: Patients over 40 years old admitted in participating emergency departments and hospitalized for acute medical reasons.
Main judgment criteria: the rate of symptomatic thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.
| Condition | Intervention |
|---|---|
|
Quality of Health Care |
Behavioral: reminders |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Prevention of Venous Thromboembolism Disease for Acutelly Ill Medical Patients Admitted to Hospital : Systematic Analysis of Thrombosis Risk Factors and Remember of Prevention Treatment Indications in Emergency Departments. |
- Symptomatic venous thromboembolic events and severe haemorrhage [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.
All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.
- Rate of symptomatic venous thromboembolic events [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]- The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission oin all included patients oin patients hospitalized at least 48 hours. oin patients hospitalized less than 48 hours
- Rate of thromboembolic events [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]- The rate of thromboembolic events oin patients who had an appropriate thromboprophylactic treatment oin patients who had an inappropriate thromboprophylactic treatment oin patients who had no thromboprophylactic treatment
- rate of severe haemorrhage [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]- The rate of severe haemorrhage oin patients who had an appropriate thromboprophylactic treatment oin patients who had an inappropriate thromboprophylactic treatment oin patients who had no thromboprophylactic treatment
- appropriateness of thromboprophylaxis [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- The appropriateness of thromboprophylaxis in the overall population and according to group assignation:
oNumber of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.
oNumber of patients without indication of thromboprophylaxis and who do not receive a treatment
Biospecimen Retention: None Retained
observational study at the patient level - cluster randomized study
| Estimated Enrollment: | 18000 |
| Study Start Date: | September 2009 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Intervention group
reminders
|
Behavioral: reminders
In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
|
|
current practice group
no intervention
|
Detailed Description:
Method:
At the end of an observational period of a week, centers will be randomized in two groups: intervention or current practice. In the intervention group, centers will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment. We will propose no change in current practice in the other group.
Primary outcome: the rate of symptomatic venous thromboembolic events and severe haemorrhage during a formal 3-months follow-up after hospital admission in patients hospitalized at least 48 hours.
All possible thromboembolic events, severe haemorrhages and deaths will be analysed by an adjudication committee blinded of group assignation. Sudden death without obvious cause according to the adjudication committee will be considered as possible fatal pulmonary embolism.
Sample size: We calculated sample size on the basis of primary outcome. Assuming the participation of 30 centers (15 in each group), an intracluster correlation of 0.01, a rate of symptomatic thromboembolic events or severe haemorrhage of 5% in the current practice group, we need a sample of 16170 patients (8085 in each group) to detect a 1.5 percentage absolute difference between the 2 groups (3.5% in the intervention group) with a power of 80% and a significance level of 5%.
Considering a rate of patients hospitalized less than 48 hours around 5% and of lost of follow-up around 3%, we anticipated to include 16500 patients for the main analysis and 18000 patients for the overall study.
Secondary outcomes:
The appropriateness of thromboprophylaxis in the overall population and according to group assignation:
- Number of patients needing prevention treatment according to international recommendations and who have an appropriate treatment.
- Number of patients without indication of thromboprophylaxis and who do not receive a treatment
The rate of symptomatic venous thromboembolic events during a formal 3-months follow-up after hospital admission
- in all included patients
- in patients hospitalized at least 48 hours.
- inpatients hospitalized less than 48 hours
The rate of thromboembolic events
- in patients who had an appropriate thromboprophylactic treatment
- in patients who had an inappropriate thromboprophylactic treatment
- in patients who had no thromboprophylactic treatment
The rate of severe haemorrhage
- in patients who had an appropriate thromboprophylactic treatment
- in patients who had an inappropriate thromboprophylactic treatment
- in patients who had no thromboprophylactic treatment
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Eligible centers: Emergency departments previously implicated in research on venous thromboembolism.
Eligible patients: patients over 40 years old admitted in participating emergency departments for non traumatic reason
Inclusion Criteria:
- age over 40 years
- Emergency department admission for non-traumatic reason
- Hospitalization in medical setting
Exclusion Criteria:
- patients less than 40 years old
- patients hospitalized in a facility which doesn't participate to the study
- 3 months follow-up not possible
- patients refusing that their personal data are used for medical research
- patients refusing to be reach for the 3 months follow-up
Contacts and Locations| Contact: Pierre-Marie ROY, MD | 00-2-41-35-37-18 | pmroy@chu-angers.fr |
| France | |
| UH Agen | Recruiting |
| Agen, France | |
| Contact: Albane Buan, MD | |
| Principal Investigator: Albane Buan, MD | |
| H Argenteuil | Recruiting |
| Argenteuil, France, 95107 | |
| Contact: Catherine Legall, MD 00-1-34-23-24-25 catherine.legall@ch-argenteuil.fr | |
| Principal Investigator: Catherine Legall, MD | |
| UH Besançon | Recruiting |
| Besançon, France, 25000 | |
| Contact: Mohamed Hachelaf, MD 00-3-81-66-88-29 mhachelaf@chu-besancon.fr | |
| Principal Investigator: Mohamed Hachelaf, MD | |
| H Bethune | Recruiting |
| Bethune, France, 62408 | |
| Contact: Alain-Eric Dubart, MD 00-3-21-64-44-44 adubart@ch-bethune.fr | |
| Principal Investigator: Alain-Eric Dubart, MD | |
| H Bobigny | Recruiting |
| Bobigny, France | |
| Contact: Adnet, MD, PhD | |
| Principal Investigator: Adnet, MD, PhD | |
| UH Ambroise Pare | Recruiting |
| Boulogne Billancourt, France, 92100 | |
| Contact: David Elkharrat, MD 00-1-49-09-55-17 david.elkharrat@apr.ap-hop.fr | |
| Principal Investigator: David Elkharrat, MD | |
| Sub-Investigator: Laurence Arrouy, MD | |
| Sub-Investigator: Caroline Guyot, MD | |
| UH Brest | Recruiting |
| Brest, France | |
| Contact: Legal, MD | |
| Principal Investigator: Legal, MD | |
| Sub-Investigator: Mottier, MD | |
| H Chateauroux | Recruiting |
| Chateauroux, France, 36019 | |
| Contact: Guillem Bouilleau, MD 00-2-54-22-88-88 guillem.bouilleau@ch-chateauroux.fr | |
| Principal Investigator: Guillem Bouilleau, MD | |
| H Clermont Ferrand | Recruiting |
| Clermont Ferrand, France | |
| Contact: Mustafa Fares, MD | |
| Principal Investigator: Mustafa Fares, MD | |
| Sub-Investigator: Jeannot Schmidt, MD, PhD | |
| H Compiegne | Recruiting |
| Compiegne, France, 60200 | |
| Contact: Patrick Miroux, MD 00-3-44-23-63-88 patrick_miroux@yahoo.fr | |
| Principal Investigator: Patrick Miroux, MD | |
| UH Dijon | Recruiting |
| Dijon, France, 21033 | |
| Contact: Didier Honnart, MD 00-3-80-29-37-46 didier.honnart@chu-dijon.fr | |
| Principal Investigator: Didier Honnart, MD | |
| UH Grenoble | Recruiting |
| Grenoble, France, 38043 | |
| Contact: Françoise Carpentier, MD 00-4-76-76-59-31 fcarpentier@chu-grenoble.fr | |
| Principal Investigator: Françoise Carpentier, MD | |
| Sub-Investigator: Claire Arasomohano, MD | |
| UH La Reunion | Recruiting |
| La Reunion, France | |
| Contact: frederic Stakowski, MD | |
| Principal Investigator: frederic Stakowski, MD | |
| UH Marseille | Recruiting |
| Marseille, France | |
| Contact: Patrick Gerbeau, MD, PhD | |
| Principal Investigator: Patrick Gerbeau, MD, PhD | |
| UH Metz Thionville | Recruiting |
| Metz, France | |
| Contact: François Braun, MD | |
| Principal Investigator: François Braun, MD | |
| UH Nantes | Recruiting |
| Nantes, France, 44100 | |
| Contact: Dominique Elkourri, MD dominique.elkourri@chu-nantes.fr | |
| Principal Investigator: Dominique Elkourri, MD | |
| UH Nimes | Recruiting |
| Nimes, France | |
| Contact: Jean Flechet, MD | |
| Principal Investigator: Jean Flechet, MD | |
| Sub-Investigator: Jean-Yves Lefrant, MD, PhD | |
| UH Bichat | Recruiting |
| Paris, France | |
| Contact: Enrique Casalino, MD, PhD | |
| Principal Investigator: Enrique Casalino, MD, PhD | |
| UH Hotel Dieu | Recruiting |
| Paris, France | |
| Contact: Florence Dumas, MD | |
| Principal Investigator: Florence Dumas, MD | |
| Sub-Investigator: Nathalie Delormes, MD | |
| H Cochin | Recruiting |
| Paris, France | |
| Contact: Yann-Eric Claessens, MD,PhD | |
| Principal Investigator: Yann-Eric Claessens, MD,PhD | |
| UH la pitié salpetriere | Recruiting |
| Paris, France, 75651 | |
| Contact: Pierre Hausfater, MD 00-1-42-17-72-68 pierre.hausfater@psl.ap-hop-paris.fr | |
| Principal Investigator: Pierre Hausfater, MD | |
| UH Poitiers | Recruiting |
| Poitiers, France | |
| Contact: Fatima Rayeh, MD | |
| Principal Investigator: Fatima Rayeh, MD | |
| UH Rennes | Recruiting |
| Rennes, France | |
| Contact: Jacques Bouget, MD, PhD | |
| Principal Investigator: Jacques Bouget, MD, PhD | |
| Principal Investigator: | Pierre-Marie ROY, MD, PhD | UH Angers |
More Information
No publications provided
| Responsible Party: | ROY Pierre-Marie, University Hospital, Angers |
| ClinicalTrials.gov Identifier: | NCT01212393 History of Changes |
| Other Study ID Numbers: | PHRC 2008-02 |
| Study First Received: | September 29, 2010 |
| Last Updated: | September 29, 2010 |
| Health Authority: | France: Institutional Ethical Committee |
Keywords provided by University Hospital, Angers:
|
venous thromboembolism disease emergency prevention thromboprophylaxis |
medical hosptitalization health care risks |
Additional relevant MeSH terms:
|
Emergencies Thromboembolism Venous Thromboembolism Venous Thrombosis Disease Attributes |
Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thrombosis |
ClinicalTrials.gov processed this record on May 21, 2013